Covishield Production

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply

With not enough orders for Covishield from the central government, Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said the company is looking at slashing the monthly production of vaccines by at least 50 percent.

The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.

Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.

Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.

The production of Covishield has been ramped up to around 110 million doses this month, Serum Institute of India (SII) sources said today as the country struggles with the supply of enough vaccines to stave off a third wave of Covid.

Serum Institute CEO Adar Poonawalla has thanked US President Joe Biden and External Affairs Minister S Jaishankar for a "policy change" that is expected to boost production of coronavirus vaccines in India and other countries

With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the target of vaccinating one crore people daily aga

External Affairs Minister S Jaishankar on Wednesday explained the difference between India's vaccine "production situation", from that of the US and said Covishield is being made in India due to its efficient production venue.

Serum Institute of India CEO Adar Poonawalla on Saturday spoke out about the pressures he was under over the production of COVID-19 vaccines to meet the ever-increasing demand in India.

The U.S. will send India raw materials for vaccines and step up financing aid for Covid-19 shot production, joining European countries in pledging help to stem the world's biggest surge in cases.

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021.

Serum Institute of India Ltd., the world's largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its stockpile grew to 200 million doses amid a global supply

With not enough orders for Covishield from the central government, Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said the company is looking at slashing the monthly production of vaccines by at least 50 percent.

The monthly vaccine production capacity of Covishield is planned to be increased from 11 crore doses to more than 12 crore doses per month and of Covaxin from 2.5 crore doses to around 5.8 crore, the Lok Sabha was informed on Friday.

Union Health Minister Mansukh Mandaviya on Friday held separate meetings with Serum Institute of India CEO Adar Poonawalla and Biological-E MD Mahima Dalta to discuss issues regarding COVID-19 vaccines.

Monthly production capacity of Covishield is projected to be increased to more than 120 million doses and of Covaxin to around 58 million doses by December, the government told Rajya Sabha today, citing information from the COVID-19 vaccine makers.

The production of Covishield has been ramped up to around 110 million doses this month, Serum Institute of India (SII) sources said today as the country struggles with the supply of enough vaccines to stave off a third wave of Covid.

Serum Institute CEO Adar Poonawalla has thanked US President Joe Biden and External Affairs Minister S Jaishankar for a "policy change" that is expected to boost production of coronavirus vaccines in India and other countries

With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the target of vaccinating one crore people daily aga

External Affairs Minister S Jaishankar on Wednesday explained the difference between India's vaccine "production situation", from that of the US and said Covishield is being made in India due to its efficient production venue.

Serum Institute of India CEO Adar Poonawalla on Saturday spoke out about the pressures he was under over the production of COVID-19 vaccines to meet the ever-increasing demand in India.

The U.S. will send India raw materials for vaccines and step up financing aid for Covid-19 shot production, joining European countries in pledging help to stem the world's biggest surge in cases.